Oncolytics Biotech Inc. highlighted compelling clinical and translational data from three metastatic colorectal cancer (mCRC) studies, demonstrating consistent efficacy signals and immune activation. In the REO 022 trial, pelareorep combined with FOLFIRI and bevacizumab in platinum refractory second-line mCRC KRAS mutant patients achieved a median progression-free survival of 4.7 months, compared to a historical benchmark of 1.9 months. The median overall survival was 11.7 months versus 4.7 months historically.
Additionally, GOBLET study's third-line mCRC Cohort 3, evaluating pelareorep with atezolizumab and TAS-102, met its predefined efficacy endpoint, showing durable disease control and survival rates exceeding historical benchmarks for TAS-102 alone. Translational data from the REO 022 trial and REO 013 study confirmed viral replication and immune activation in mCRC tumors, including dendritic cell maturation and CD8+ T cell activation.
These findings validate pelareorep's mechanism of action, confirming its ability to modify mCRC tumors to be immune responsive. Oncolytics plans to initiate an investigator-sponsored trial to further explore pelareorep's potential in KRAS mutant mCRC and will engage with regulators to define a clear path to registration, including the design of a confirmatory study in this underserved patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.